ReviewThe AAPS journal2013
A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms.
Review in The AAPS journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Assessment of Taste and Grittiness of RiometDrugs in R&D · 2019Trial
- Parent-Reported Satisfaction, Perceived Child Acceptance, and Ease of Administration of a Strawberry-Flavoured Ibuprofen Suspension for Children: A Cross-Sectional Survey of Experienced Users in Germany.Journal of market access & health policy · 2026Article
- Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access.Clinical pharmacology and therapeutics · 2026Review
- Suitability of Oral Formulations Available to Children at the Time of Pediatric Labeling.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Extemporaneous Cyclodextrin-Based Oral Solution of Ursodeoxycholic Acid Using a Ready-to-Use Vehicle.Pharmaceutics · 2026Article
- An Interactive Constraint-Based Decision-Support Tool for Pharmaceutical Formulation Development.Pharmaceutics · 2026Article
- Personal variation in the palatability and side effects of liquid clindamycin among children.Pediatric research · 2026Article
- Challenges in the Oral Administration of Gastro-Resistant Formulations: The Role of Vehicles and Bottled Waters.Pharmaceutics · 2026Article
- Electrochemical Sensors as a Tool for Taste Perception in Pharmaceutical Products: Advances and Perspectives.Biosensors · 2026Review
- Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges.CPT: pharmacometrics & systems pharmacology · 2026Review
- Three-Dimensionally Printed Paediatric Medicines: Formulation, Process, and Regulatory Considerations.Pharmaceutics · 2025Review
- Three-Dimensional Printing in Paediatrics: Innovative Technology for Manufacturing Patient-Centred Drug Delivery Systems.Pharmaceutics · 2025Review
- Choosing the "Ideal" Oral Dosage Form for Pediatric Patients: Parents' Perspectives on Children's Preferences with a Focus on Orodispersible Tablets.Children (Basel, Switzerland) · 2025Article
- Functional and Safety Profile ofPharmaceutics · 2025Article
- Development and Characterization of Cannabidiol Gummy Using 3D Printing.Gels (Basel, Switzerland) · 2025Article
- Study on Lyophilised Orodispersible Tablets from Plant-Based Drinks as Bulking Agents.Pharmaceutics · 2025Article
- Assessing solubility of meloxicam in age-specific gastric and intestinal media relevant to adults and pediatric populations: implications for optimizing dosing in patients for postoperative pain.BMC pharmacology & toxicology · 2024Article
- Conducting Drug Treatment Trials in Children: Opportunities and Challenges.Pharmaceutical medicine · 2024Review
- Parents' Perceptions Regarding Their Children's Medications and Expert-Assessed Drug-Related Problems in Pediatric Patients with Inborn Errors of Metabolism.Children (Basel, Switzerland) · 2023Article
- A novel home-based method for preparing suspensions of anti-TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the fact that a significant percentage of the population is unable to swallow tablets and capsules, these dosage forms continue to be the default standard. These oral formulations fail many patients, especially children, because of large tablet or capsule size, poor palatability, and lack of correct dosage strength. The clinical result is often lack of adherence and therapeutic failure. The American Association of Pharmaceutical Scientists formed a Pediatric Formulations Task Force, consisting of members with various areas of expertise including pediatrics, formulation development, clinical pharmacology, and regulatory science, in order to identify pediatric, manufacturing, and regulatory issues and areas of needed research and regulatory guidance. Dosage form and palatability standards for all pediatric ages, relative bioavailability requirements, and small batch manufacturing capabilities and creation of a viable economic model were identified as particular needs. This assessment is considered an important first step for a task force seeking creative approaches to providing more appropriate oral formulations for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.